CLAIMS

1. Use of ~~A~~a veterinary composition comprising artesunate or a salt thereof, and a pharmaceutically acceptable excipient, in the manufacture of a medicament for ~~use for~~ preventing and/or treating leishmaniosis in a dog.

2. ~~A veterinary composition for~~ The use according to claim 1, wherein said dog is a *Leishmania infantum* naturally infected dog.

3. ~~A veterinary composition for~~The use according to claim 1 or 2, wherein said veterinary comprises a therapeutically efficient dose comprised between 0.1 and 100 mg/kg BW/day, preferably between 1 and 50 mg/kg BW/day, more preferably between 20 and 30 mg/kg BW/day.

4. ~~A veterinary composition for~~The use according to any one of claims 1 to 3, wherein said veterinary composition comprises a therapeutically efficient dose of 25 mg/kg BW/day.

5. ~~A veterinary composition for~~The use according to any one of claims 1 to 4, wherein said veterinary composition is to be administered by an oral route.

6. ~~A veterinary composition for~~The use according to any one of claims 1 to 5, wherein said veterinary composition is a tablet.

7. ~~A veterinary composition for~~The use according to any one of claims 1 to 6, wherein said veterinary composition is to be administered in a single daily dose.

8. ~~A veterinary composition for~~ The use according to any one of claims 1 to 7, wherein said veterinary composition is to be administered for at least 6 days, preferably from 6 to 10 days, more preferably for 6 days.

9. ~~A veterinary composition for~~The use according to any one of claims 1 to 8, for controlling the clinical signs of leishmaniosis.

10. ~~A veterinary composition for~~The use according to any one of claims 1 to 8, for controlling *Leishmania infantum* blood load.

11. ~~A veterinary composition for~~The use according to any one of claims 1 to 8, for controlling *Leishmania infantum* antibodies.

12. Use of ~~A~~a veterinary composition comprising artesunate or a salt thereof, and a pharmaceutically acceptable excipient, in the manufacture of a medicament for ~~use for~~ preventing and/or treating leishmaniosis in *a Leishmania infantum* naturally infected dog, wherein said veterinary composition is to be administered to said infected dog by oral route in a single daily dose of 25 mg/kg BW/day for 6 days.

13. ~~A veterinary composition for~~ The use according to any one of claims 1 to 12, wherein said veterinary composition further comprises at least one antiparasitic agent.

14. A kit comprising a first compartment comprising artesunate or a salt thereof, and a second compartment comprising at least one antiparasitic agent as a combined preparation for simultaneous, separate, or sequential use, in particular for preventing and/or treating leishmaniosis in a dog, said kit optionally comprises a notice or an instruction guide.